甲磺酸卡莫司他可减轻2019冠状病毒病脓毒症严重程度:首次观察
该回顾性观察性病例系列纳入德国哥廷根大学医院ICU收治的11例伴器官衰竭的危重型2019冠状病毒病患者,其中6例 compassionate use 接受甲磺酸卡莫司他(卡莫司他组),5例接受羟氯喹(羟氯喹组)。以第1、3、8天脓毒症相关器官衰竭评估评分评估临床病程,并检测病毒载量、氧合和炎症标志物。两组入ICU时脓毒症相关器官衰竭评估评分相当,观察期间卡莫司他组评分下降而羟氯喹组仍升高,卡莫司他组疾病严重程度下降伴随炎症标志物下降和氧合改善。作者结论为甲磺酸卡莫司他治疗8天内2019冠状病毒病严重程度下降,羟氯喹组未观察到类似效果,因此甲磺酸卡莫司他值得在随机临床试验中进一步评估。
要点
- 11例ICU危重型2019冠状病毒病伴器官衰竭患者中,6例接受甲磺酸卡莫司他、5例接受羟氯喹。
- 两组入ICU时脓毒症相关器官衰竭评估评分相当,观察期间卡莫司他组评分下降而羟氯喹组仍升高。
- 卡莫司他组疾病严重程度下降伴随炎症标志物下降和氧合改善。
- 作者结论:甲磺酸卡莫司他治疗8天内2019冠状病毒病严重程度下降,羟氯喹组未观察到类似效果。
- 作者认为甲磺酸卡莫司他值得在随机临床试验中进一步评估。
适用人群与场景
- 德国哥廷根大学医院ICU收治的11例危重型2019冠状病毒病伴器官衰竭患者。
处置流程与药物剂量
- 甲磺酸卡莫司他组6例以 compassionate use 方式接受甲磺酸卡莫司他治疗。
- 羟氯喹组5例接受羟氯喹治疗。
研究设计与关键结果
- 研究类型为回顾性观察性病例系列,样本量11例,人群为ICU危重型2019冠状病毒病伴器官衰竭患者,干预为 compassionate use 甲磺酸卡莫司他(6例)或羟氯喹(5例)。
- 两组入ICU时脓毒症相关器官衰竭评估评分相当;观察期间卡莫司他组评分下降而羟氯喹组仍升高。
- 卡莫司他组疾病严重程度下降伴随炎症标志物下降和氧合改善。
证据类型、等级与局限
- 证据类型:回顾性观察性病例系列。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为甲磺酸卡莫司他值得在随机临床试验中进一步评估。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Severe acute respiratory syndrome coronavirus 2 cell entry depends on angiotensin-converting enzyme 2 and transmembrane serine protease 2 and is blocked in cell culture by camostat mesylate, a clinically proven protease inhibitor. Whether camostat mesylate is able to lower disease burden in coronavirus disease 2019 sepsis is currently unknown.
DESIGN: Retrospective observational case series.
SETTING: Patient treated in ICU of University hospital Göttingen, Germany.
PATIENTS: Eleven critical ill coronavirus disease 2019 patients with organ failure were treated in ICU.
INTERVENTIONS: Compassionate use of camostat mesylate (six patients, camostat group) or hydroxychloroquine (five patients, hydroxychloroquine group).
MEASUREMENTS AND MAIN RESULTS: Clinical courses were assessed by Sepsis-related Organ Failure Assessment score at days 1, 3, and 8. Further, viral load, oxygenation, and inflammatory markers were determined. Sepsis-related Organ Failure Assessment score was comparable between camostat and hydroxychloroquine groups upon ICU admission. During observation, the Sepsis-related Organ Failure Assessment score decreased in the camostat group but remained elevated in the hydroxychloroquine group. The decline in disease severity in camostat mesylate treated patients was paralleled by a decline in inflammatory markers and improvement of oxygenation.
CONCLUSIONS: The severity of coronavirus disease 2019 decreased upon camostat mesylate treatment within a period of 8 days and a similar effect was not observed in patients receiving hydroxychloroquine. Camostat mesylate thus warrants further evaluation within randomized clinical trials.
参考来源
- Hofmann-Winkler H, Moerer O, Alt-Epping S, et al. Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation. Crit Care Explor. 2020. PMID: 33225308. doi:10.1097/CCE.0000000000000284
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。